Dali Pharmaceuticalco.Ltd Past Earnings Performance
Past criteria checks 0/6
Dali Pharmaceuticalco.Ltd's earnings have been declining at an average annual rate of -43.5%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 28.4% per year.
Key information
-43.5%
Earnings growth rate
-43.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -28.4% |
| Return on equity | -6.7% |
| Net Margin | -39.5% |
| Last Earnings Update | 30 Sep 2024 |
Revenue & Expenses Breakdown
How Dali Pharmaceuticalco.Ltd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 62 | -24 | 30 | 1 |
| 30 Jun 24 | 55 | -21 | 32 | 1 |
| 31 Mar 24 | 66 | -23 | 41 | 1 |
| 31 Dec 23 | 87 | -20 | 57 | 1 |
| 30 Sep 23 | 105 | -22 | 73 | 1 |
| 30 Jun 23 | 122 | -20 | 84 | 1 |
| 31 Mar 23 | 129 | -17 | 86 | 1 |
| 31 Dec 22 | 132 | -18 | 93 | 1 |
| 30 Sep 22 | 143 | -47 | 100 | 1 |
| 30 Jun 22 | 149 | -49 | 110 | 1 |
| 31 Mar 22 | 162 | -45 | 127 | 2 |
| 31 Dec 21 | 171 | -42 | 134 | 1 |
| 30 Sep 21 | 181 | -8 | 144 | 2 |
| 30 Jun 21 | 202 | 2 | 152 | 2 |
| 31 Mar 21 | 218 | 5 | 158 | 2 |
| 31 Dec 20 | 214 | 3 | 152 | 3 |
| 30 Sep 20 | 227 | 4 | 158 | 2 |
| 30 Jun 20 | 237 | 2 | 166 | 3 |
| 31 Mar 20 | 256 | 5 | 180 | 3 |
| 31 Dec 19 | 294 | 14 | 206 | 2 |
| 30 Sep 19 | 324 | 20 | 228 | 2 |
| 30 Jun 19 | 359 | 22 | 257 | 2 |
| 31 Mar 19 | 374 | 9 | 290 | 2 |
| 31 Dec 18 | 401 | 11 | 306 | 2 |
| 30 Sep 18 | 385 | 11 | 296 | 2 |
| 30 Jun 18 | 346 | 14 | 255 | 4 |
| 31 Mar 18 | 321 | 35 | 194 | 3 |
| 31 Dec 17 | 273 | 44 | 131 | 3 |
| 30 Sep 17 | 301 | 66 | 91 | 3 |
| 31 Dec 16 | 276 | 62 | 51 | 0 |
| 31 Dec 15 | 267 | 62 | 46 | 0 |
| 31 Dec 14 | 339 | 100 | 43 | 0 |
| 31 Dec 13 | 298 | 92 | 41 | 0 |
Quality Earnings: 603963 is currently unprofitable.
Growing Profit Margin: 603963 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603963 is unprofitable, and losses have increased over the past 5 years at a rate of 43.5% per year.
Accelerating Growth: Unable to compare 603963's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 603963 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.5%).
Return on Equity
High ROE: 603963 has a negative Return on Equity (-6.75%), as it is currently unprofitable.